Drug Trial Radar · NCT04565275
A Study of ICP-192 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
45
Planned (sponsor's estimate)
Start
Feb 1, 2021
Primary completion
Nov 30, 2023
Study completion Apr 15, 2024
Sponsor
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 25, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label, phase I/II clinical study to evaluate ICP-192 in patients with advanced solid tumors and FGFR gene alterations. It consists of two parts: Part I (Phase I), dose escalation and Part II (Phase II), dose expansion.
Conditions
- Advanced Solid Tumors
- Urothelial Carcinoma
- Cholangiocarcinoma
Interventions
Drug ICP-192Drug
1. Dose Escalation Phase ICP-192 will be taken by patients with advanced solid tumor and will be treated follow the "3+3" dose escalation scheme 2. Dose Expansion Phase ICP-192 will be taken by patients with urothelial carcinoma or cholangiocarcinoma with FGFR gene alterations and will be treated at a single dose defined from the Dose Escalation Phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Up to 3 years
- MTDTime frame: Up to 3 years
- OBDTime frame: Up to 3 years
- RP2DTime frame: Up to 3 years
- ORRTime frame: Up to 3 years
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
Arizona Oncology
Tucson, Arizona · Recruiting
University of California, San Diego (UCSD) - Moores Cancer Center
La Jolla, California · Recruiting
Rocky Mountain Cancer Centers
Aurora, Colorado · Recruiting
Mid Florida Hematology and Oncology
Orange City, Florida · Not yet recruiting
Minnesota Oncology Hematology
Minneapolis, Minnesota · Recruiting
Clinical Research Alliance
Lake Success, New York · Recruiting
Rutgers Cancer Institute of New Jersey
The Bronx, New York · Recruiting
The Ohio State University
Columbus, Ohio · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Macquarie University Hospital
Macquarie Park, New South Wales, Australia · Recruiting
GenesisCare - North Shore
St Leonards, New South Wales, Australia · Recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
Pindara Private Hospital
Benowa, Queensland, Australia · Recruiting
Monash Medical Centre Clayton
Clayton, Victoria, Australia · Recruiting
Peninsula & South Eastern Haematology & Oncology Group
Frankston, Victoria, Australia · Recruiting
Olivia Newton-John Cancer Research Institute
Melbourne, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.